Fda grants latozinemab breakthrough therapy designation for frontotemporal dementia due to a progranulin gene mutation (ftd-grn)

-latozinemab is the most advanced progranulin-elevating candidate in development for ftd-grn and has now become the first investigational medicine to receive a breakthrough therapy designation for the treatment of ftd-grn-
ALEC Ratings Summary
ALEC Quant Ranking